查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1971075

传染性肠炎治疗市场－全球产业规模、份额、趋势、机会、预测：按给药途径、药物类型、地区和竞争格局划分，2021-2031年

Infectious Enteritis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Route of Administration (Oral, Injectables), By Drug Type (Antibiotics, Antivirals, Others), By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球传染性肠胃炎治疗市场预计将从 2025 年的 5.1221 亿美元大幅成长至 2031 年的 7.9182 亿美元，复合年增长率为 7.53%。

此市场领域涵盖抗生素和抗病毒药物等药物疗法，以及用于治疗由病原微生物引起的肠道发炎的补液疗法。推动成长的关键因素是全球腹泻疾病发生率的上升，以及由于医疗基础设施投资增加而带来的基本药物可近性提高。例如，世界卫生组织（世卫组织）报告称，2024年全球霍乱病例将比前一年增加5%，凸显了对有效治疗性介入的持续需求，以及受影响全部区域持续的需求。

市场概览
预测期 2027-2031
市场规模：2025年 5.1221亿美元
市场规模：2031年 7.9182亿美元
复合年增长率：2026-2031年 7.53%
成长最快的细分市场 口服
最大的市场 北美洲

阻碍市场发展的主要障碍是肠道病原体对抗生素抗药性的日益增强。多重抗药性菌株的传播降低了标准抗生素疗法的疗效，导致临床结果复杂，需要更精细的治疗通讯协定。这个问题迫使製药企业投入巨资研发替代疗法，从而设置了重大的监管和经济壁垒，限制了市场准入和成长。

市场驱动因素

全球食源性和水源性肠道感染疾病的增加是市场需求的主要驱动因素。诺罗病毒、沙门氏菌和李斯特菌等病原体正透过复杂的供应链和不完美的卫生措施传播。根据英国健康安全局 (UKHSA) 2024 年 4 月发布的《国家诺罗病毒和轮状病毒报告》，诺罗病毒检测报告数量比过去五年的平均水平高出 75%，凸显了疫情的波动性以及建立健全的口服补液盐和症状管理药物供应链的紧迫性。此外，美国疾病管制与预防中心 (CDC) 于 2024 年报告了一起与熟食肉品相关的单核细胞增生李斯特菌感染疾病的严重集体爆发，导致 57 人住院治疗。这再次强调了强而有力的抗生素介入和医院治疗方法的重要性。

同时，对新型抗菌和抗病毒疗法研发投入的增加正在改变竞争格局。随着传统抗生素对抗药性细菌的疗效下降，公部门和私部门都在集中资金研发下一代治疗方法。例如，英国政府于2024年5月宣布拨款8,500万英镑，专门用于支持抗菌素抗药性研究和新型感染疾病治疗方法的开发。这项财政支持将使製药公司能够加快临床试验并克服监管障碍，从而确保持续供应先进治疗方法，以应对不断演变的病原体威胁。

市场挑战

抗生素抗药性的蔓延是感染性肠炎治疗市场成长的一大障碍。随着越来越多的肠道病原体对标准抗生素疗法产生抗药性，现有药物疗法的临床价值下降，迫使製药公司投入大量研发新化合物。这项转型需要进行复杂且成本高昂的研发倡议，失败风险也高，导致利润率下降，并阻碍新进者。因此，开发替代疗法所带来的经济负担造成了限制性的经济环境，阻碍了治疗方案的商业性扩充性。

近期监测数据进一步凸显了这个挑战，凸显了问题的严重性。 2024年，欧洲疾病预防控制中心报告称，在报告国家中，65.7%的人源性曲状桿菌桿菌分离株对Ciprofloxacin有抗药性。如此高的抗药性加速了一线治疗药物的过时，并大幅缩短了现有治疗方法的寿命。因此，市场面临着产品持续贬值的恶性循环，阻碍了长期收入成长，并使维持有效药物稳定供应所需的策略规划更加复杂。

市场趋势

市场正经历着向微生物组调节疗法的显着转变，尤其是在艰难梭菌感染疾病的治疗方面，这种感染即使在接受标准抗生素治疗后也容易復发。与破坏肠道生态系统的传统抗菌药物不同，这些生物治疗产品旨在恢復肠道菌群，防止病原体再次定植，并打破復发循环。 VOWST 的成功为这一趋势提供了商业性支持，VOWST 是 FDA 批准的首个口服微生物组疗法。 Seres Therapeutics 公司报告称，该药物在 2024 年 5 月的第一季净销售额达到 1,010 万美元，表明胃肠病学家正在迅速接受这种药物，以寻求标准疗法的替代方案。

同时，快速照护现场分子诊断技术的引入正在变革临床管理。针对特定综合征的检测组合取代了传统的培养方法，使医护人员能够从一份粪便检体中检测出多种病毒、细菌和寄生虫病原体，从而显着缩短诊断时间，并实现靶向性强、频谱窄的治疗。生物梅里埃公司2024年9月发布的报告清楚展现了这些诊断组合的商业性成功。报告指出，BIOFIRE非呼吸道检测组合（包括胃肠道解决方案）的销售额在上半年实现了19%的内部成长，从而支持了更精准的治疗方法和更优化的患者隔离通讯协定。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球传染性肠炎治疗市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 给药途径（口服、注射）
    • 依药物类型（抗生素、抗病毒药物、其他）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美感染性肠炎治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲传染性肠炎治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区感染性肠炎治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲感染性肠炎治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲传染性肠炎治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章 全球传染性肠炎治疗市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Novartis AG
  • Gilead Sciences Inc
  • GlaxoSmithKline plc
  • Janssen Global Services, LLC
  • F. Hoffmann-La Roche Ltd.
  • BioCryst Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Boehringer Ingelheim GmbH
  • Sanofi AG
  • Medtronic Plc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 23954

The Global Infectious Enteritis Treatment Market is projected to expand significantly, rising from USD 512.21 Million in 2025 to USD 791.82 Million by 2031, reflecting a compound annual growth rate of 7.53%. This market sector includes pharmacotherapies like antibiotics and antivirals, as well as rehydration regimens designed to manage intestinal inflammation induced by pathogenic microorganisms. Growth is primarily underpinned by the increasing global incidence of diarrheal diseases and enhanced investment in healthcare infrastructure, which broadens access to vital medicines. For instance, the World Health Organization reported a 5% increase in global cholera cases in 2024 compared to the previous year, highlighting a persistent necessity for effective therapeutic interventions and ensuring sustained demand across affected regions.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 512.21 Million
Market Size 2031USD 791.82 Million
CAGR 2026-20317.53%
Fastest Growing SegmentOral
Largest MarketNorth America

A major obstacle hindering market progression is the rising prevalence of antimicrobial resistance among enteric pathogens. The spread of multidrug-resistant bacterial strains diminishes the efficacy of standard antibiotic treatments, resulting in complicated clinical outcomes and the need for intricate treatment protocols. This issue compels pharmaceutical developers to bear substantial costs in the pursuit of alternative therapies, establishing significant regulatory and economic barriers that limit market accessibility and growth.

Market Driver

The rising global prevalence of foodborne and waterborne enteric infections serves as a primary driver for market demand, as pathogens like Norovirus, Salmonella, and Listeria spread through complex supply chains and hygiene lapses. According to the United Kingdom Health Security Agency's 'National Norovirus and Rotavirus Report' from April 2024, laboratory reports of norovirus were 75% higher than the five-year average, underscoring the volatility of outbreaks and the urgent need for robust supply chains for rehydration salts and symptom-management drugs. Additionally, the Centers for Disease Control and Prevention noted a severe Listeria monocytogenes outbreak linked to deli meats in 2024 that caused 57 hospitalizations, reinforcing the critical necessity for potent antibiotic interventions and hospital-grade therapies.

Simultaneously, increased investment in research and development for novel antimicrobial and antiviral therapies is transforming the competitive landscape. To address the waning effectiveness of traditional antibiotics against resistant strains, both public and private sectors are directing capital toward next-generation treatments. For example, the United Kingdom Government announced an £85 million commitment in May 2024 specifically to support research into antimicrobial resistance and the development of new infectious disease treatments. This financial support helps pharmaceutical companies expedite clinical trials and navigate regulatory hurdles, ensuring a continuous pipeline of advanced therapeutic options to tackle evolving pathogenic threats.

Market Challenge

The growing prevalence of antimicrobial resistance poses a significant hurdle to the growth of the infectious enteritis treatment market. As enteric pathogens increasingly survive standard antibiotic regimens, the clinical value of existing pharmacotherapies declines, compelling pharmaceutical developers to invest heavily in discovering novel compounds. This transition requires complex, expensive research initiatives with high risks of failure, which reduces profit margins and deters new market entrants. Consequently, the financial strain of developing alternative therapies creates a restrictive economic climate that hampers the commercial scalability of treatment portfolios.

This challenge is reinforced by recent surveillance data highlighting the severity of the problem. In 2024, the European Centre for Disease Prevention and Control reported that 65.7% of Campylobacter coli isolates in humans across reporting countries were resistant to ciprofloxacin. Such high resistance rates hasten the obsolescence of frontline treatments, effectively shortening the viable lifespan of current inventories. As a result, the market contends with a continuous cycle of product devaluation, which obstructs long-term revenue growth and complicates the strategic planning necessary to maintain a steady supply of effective medicines.

Market Trends

The market is experiencing a significant shift toward microbiome-modulating therapeutics, particularly for managing recurrent Clostridioides difficile infections that frequently succeed standard antibiotic treatments. Unlike traditional antimicrobials that disturb gut ecology, these live biotherapeutic products are engineered to restore the intestinal microbial community, preventing pathogen recolonization and halting the cycle of recurrence. This trend is commercially supported by the success of the first FDA-approved oral microbiome therapy, VOWST; Seres Therapeutics reported in May 2024 that net sales for the drug reached $10.1 million in the first quarter, indicating rapid adoption by gastroenterologists seeking alternatives to standard care.

Concurrently, clinical management is being transformed by the adoption of rapid point-of-care molecular diagnostics, which replace slower culture methods with syndromic panel testing. These advanced platforms allow healthcare providers to detect a wide range of viral, bacterial, and parasitic pathogens from a single stool sample, drastically reducing diagnosis time and enabling targeted, narrow-spectrum treatment. The commercial success of these panels is evident in bioMerieux's September 2024 report, which noted that sales of BIOFIRE non-respiratory panels, including gastrointestinal solutions, grew organically by 19% in the first half of the year, supporting a more precise therapeutic approach and optimized patient isolation protocols.

Key Market Players

  • Novartis AG
  • Gilead Sciences Inc
  • GlaxoSmithKline plc
  • Janssen Global Services, LLC
  • F. Hoffmann-La Roche Ltd.
  • BioCryst Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Boehringer Ingelheim GmbH
  • Sanofi A.G.
  • Medtronic Plc.

Report Scope

In this report, the Global Infectious Enteritis Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Infectious Enteritis Treatment Market, By Route of Administration

  • Oral
  • Injectables

Infectious Enteritis Treatment Market, By Drug Type

  • Antibiotics
  • Antivirals
  • Others

Infectious Enteritis Treatment Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Infectious Enteritis Treatment Market.

Available Customizations:

Global Infectious Enteritis Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Infectious Enteritis Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Route of Administration (Oral, Injectables)
    • 5.2.2. By Drug Type (Antibiotics, Antivirals, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Infectious Enteritis Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Route of Administration
    • 6.2.2. By Drug Type
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Infectious Enteritis Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Route of Administration
        • 6.3.1.2.2. By Drug Type
    • 6.3.2. Canada Infectious Enteritis Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Route of Administration
        • 6.3.2.2.2. By Drug Type
    • 6.3.3. Mexico Infectious Enteritis Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Route of Administration
        • 6.3.3.2.2. By Drug Type

7. Europe Infectious Enteritis Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Route of Administration
    • 7.2.2. By Drug Type
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Infectious Enteritis Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Route of Administration
        • 7.3.1.2.2. By Drug Type
    • 7.3.2. France Infectious Enteritis Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Route of Administration
        • 7.3.2.2.2. By Drug Type
    • 7.3.3. United Kingdom Infectious Enteritis Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Route of Administration
        • 7.3.3.2.2. By Drug Type
    • 7.3.4. Italy Infectious Enteritis Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Route of Administration
        • 7.3.4.2.2. By Drug Type
    • 7.3.5. Spain Infectious Enteritis Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Route of Administration
        • 7.3.5.2.2. By Drug Type

8. Asia Pacific Infectious Enteritis Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Route of Administration
    • 8.2.2. By Drug Type
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Infectious Enteritis Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Route of Administration
        • 8.3.1.2.2. By Drug Type
    • 8.3.2. India Infectious Enteritis Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Route of Administration
        • 8.3.2.2.2. By Drug Type
    • 8.3.3. Japan Infectious Enteritis Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Route of Administration
        • 8.3.3.2.2. By Drug Type
    • 8.3.4. South Korea Infectious Enteritis Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Route of Administration
        • 8.3.4.2.2. By Drug Type
    • 8.3.5. Australia Infectious Enteritis Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Route of Administration
        • 8.3.5.2.2. By Drug Type

9. Middle East & Africa Infectious Enteritis Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Route of Administration
    • 9.2.2. By Drug Type
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Infectious Enteritis Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Route of Administration
        • 9.3.1.2.2. By Drug Type
    • 9.3.2. UAE Infectious Enteritis Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Route of Administration
        • 9.3.2.2.2. By Drug Type
    • 9.3.3. South Africa Infectious Enteritis Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Route of Administration
        • 9.3.3.2.2. By Drug Type

10. South America Infectious Enteritis Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Route of Administration
    • 10.2.2. By Drug Type
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Infectious Enteritis Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Route of Administration
        • 10.3.1.2.2. By Drug Type
    • 10.3.2. Colombia Infectious Enteritis Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Route of Administration
        • 10.3.2.2.2. By Drug Type
    • 10.3.3. Argentina Infectious Enteritis Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Route of Administration
        • 10.3.3.2.2. By Drug Type

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Infectious Enteritis Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Novartis AG
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Gilead Sciences Inc
  • 15.3. GlaxoSmithKline plc
  • 15.4. Janssen Global Services, LLC
  • 15.5. F. Hoffmann-La Roche Ltd.
  • 15.6. BioCryst Pharmaceuticals, Inc.
  • 15.7. Merck & Co., Inc.
  • 15.8. Boehringer Ingelheim GmbH
  • 15.9. Sanofi A.G.
  • 15.10. Medtronic Plc.

16. Strategic Recommendations

17. About Us & Disclaimer